Inhibrx Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Inhibrx, Inc. (INBX)
Company Research
Source: Yahoo! Finance
Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.) Recent Corporate Highlights On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing sarcoma expansion cohorts. Ozekibart met its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo. Key secondary endpoints reinforce the primary benefit, demonstrating meaningful improvements in disease control and patient quality of life. Inhibrx plans to submit to the U.S. Food and Drug Administration a biol
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap [Seeking Alpha]Seeking Alpha
- Inhibrx Biosciences (NASDAQ:INBX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Inhibrx Biosciences GAAP EPS of -$2.28 [Seeking Alpha]Seeking Alpha
- Inhibrx Reports Third Quarter 2025 Financial ResultsPR Newswire
- Inhibrx Announces Participation in Upcoming Scientific Conferences [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 8/13/25 - Beat
INBX
Analyst Actions
- 11/19/25 - Citigroup Inc.
INBX
Sec Filings
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- 10/23/25 - Form 8-K
- INBX's page on the SEC website